Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group

Autor: Francesca Fazio, Luca Franceschini, Valeria Tomarchio, Angela Rago, Maria Grazia Garzia, Luca Cupelli, Velia Bongarzoni, Alessandro Andriani, Svitlana Gumenyuk, Agostino Tafuri, Agostina Siniscalchi, Alfonso Piciocchi, Paolo De Fabritiis, Luca De Rosa, Tommaso Caravita di Toritto, Ombretta Annibali, Maria Cantonetti, Maria Teresa Petrucci

Publikováno v: eJHaem, Vol 3, Iss 1, Pp 121-128 (2022)

Abstract The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD

Externí odkaz: https://doaj.org/article/08a8f52370794db1965593a53d936007

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies

Autor: Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, Gianluca Gaidano, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Stefano Spada, Giulia Benevolo, Elena Ponticelli, Piero Galieni, Michele Cavo, Tommaso Caravita Di Toritto, Francesco Di Raimondo, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro, Alessandra Larocca

Publikováno v: Haematologica, Vol 104, Iss 8 (2019)

Twice-weekly carfilzomib is approved at 27 and 56 mg/m2 to treat relapsed multiple myeloma patients. In the phase III study ARROW, once-weekly 70 mg/m 2 carfilzomib prolonged the median progression-free survival of relapsed multiple myeloma patients

Externí odkaz: https://doaj.org/article/760e660fcbbe4f68ab668326a516ecbe

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

Autor: Martin Kropff, Honorata Giongco Baylon, Jens Hillengass, Tadeusz Robak, Roman Hajek, Peter Liebisch, Stefan Goranov, Cyrille Hulin, Joan Bladé, Tommaso Caravita, Herve Avet-Loiseau, Thomas M. Moehler, Claire Pattou, Lela Lucy, Elisabeth Kueenburg, Axel Glasmacher, Robert Zerbib, Thierry Facon

Publikováno v: Haematologica, Vol 97, Iss 5 (2012)

Background Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma.Design and Methods We conducted an international, rand

Externí odkaz: https://doaj.org/article/b15bdc7adca2460fa448a49377a7764a

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Autor: Meletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, Sebastian Grosicki, Michele Cavo, Meral Beksaç, Wojciech Legieć, Anna M Liberati, Hartmut Goldschmidt, Andrew Belch, Hila Magen, Alessandra Larocca, Jacob P Laubach, Maria T Petrucci, Donna Reece, Darrell White, María-Victoria Mateos, Ivan Špička, Mihaela Lazaroiu, Jesús Berdeja, Jonathan L Kaufman, Ying-Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Irwindeep Sandhu, Monika Podhorecka, Antonio Palumbo, Adi Shacham-Abulafia, Iuliana Vaxman, Ofer Shpilberg, Britta Besemer, Maurizio Martelli, Roberto Foà, Paolo De Fabritiis, Tommaso Caravita di Toritto, Emanuil Gheorghita, Albert Oriol, Philip Rowlings, Angelucci Emanuele, Angelo M Carella, Massimo Offidani, Joan Bladé, Luis F Casado, Heather Oakervee, Victoria Panelli, Luis Meza, Thomas Kühr, Miguel Granell, Don Benson, Rajesh Nair, Viran Holden, James Reeves, Richard W Eek, Patricia A Walker, John Catalano, András Rosta, Ewa Lech-Marańda, Christy Samaras, Anthony Reiman, Robert Weaver, Peter Acs, Andrew Grigg, Bernard De Prijck, Martha Louzada, Leonard Minuk, Michael Sebag, Martine Klausmann, Manfred Welslau, Andrzej Hellmann, Catalin Danaila, Pamela Becker, William Bensinger, Bruce Porterfield, Manuel Modiano, Stephen M Schultz, Robert Manges, Huey-Shin Cindy Lee, James X Gray, Matthew P Wright, Marie-Christine Vekemans, Aryan Hamed, Zoltán Gasztonyi, Gábor Mikala, Tamás Masszi, Barbara Gamberi, Kazimierz Kuliczkowski, Lidia Usnarska-Zubkiewicz, Enrique Bengoechea, María AE Gutiérrez, Miguel TH García, Jesús San-Miguel, Christoph Driessen, Rajesh Behl, Warren Brenner, Carl Gray, Vincent Hansen, Mehdi Moezi, Hector V Cortes, Charles Yen, Laurent Gressot, Noemi Horvath, James M D'Rozario, Maya Latimer, Maria-Christine Kyrtsonis, Evgeni Chubar, Moshe Mittelman, Luca Baldini, Patrizia Tosi, Angelo Vacca, Wiesław W Jędrzejczak, Tadeusz Robak, Juan J Lahuerta, Jennifer Carney, Franklin Chen, Robert Hirsch, Marco Ruiz, Alvaro Alencar, Madan Jagasia, Samer Kasbari, Philip Kuriakose, Aftab Mahmood, Madhu Chaudhry, Gary Cohen, Stephen Noga, Sch Roa, Andrzej Jakubowiak, Cara Rosenbaum, Michel Delforge, Vanessa Delrieu, Chantal Doyen, Deeren Dries, Hilde Demuynck, Rik Schots, Vladimir Maisnar, Igor W Blau, Heinz A Dürk, Andrea Kerkhoff, Martin Kropff, Markus Munder, Christoph Röllig, Christof Scheid, Argiris S Symeonidis, Árpád Illés, Mark Coyne, Peter O'Gorman, Patrick Hayden, Michael O'Dwyer, Dina Ben-Yehuda, Andrei Braester, Anatoly Nemets, Gilles Lugassy, Yossi Cohen, Naomi Rahimi-Levene, Alberto Bosi, Sara Pezzatti, Fausto Rossini, Enrico M Pogliani, Antonello Pinto, Mieczysław Komarnicki, Gabriela Borsaru, Razvan Stoia, Boris Afanasyev, María A Goñi, Ana V Carboneras, Sarah Ali, S. Eric Rubenstein, Salvador Caputto, Thomas Cosgriff, Suzanne Fanning, Ali Khojasteh, Andrew Liman, Albert Malcolm, Nandagopal Vrindavanam, Ravindranath Patel, Rajesh Belani, Marie Shieh, Keith Stockerl-Goldstein, Charles Strnad, Robert Stuart, Saurabh Chhabra, Luciano Costa, Haresh Jhangiani, Bradley Augustson, Robin Filshie, Amanda Johnston, Mark S Hertzberg, Philippe Mineur, Susan Fox, Rami Kotb, Vi Dao, Richard LeBlanc, Evzen Gregora, Annamaria Brioli, Lars-Olof Mügge, Mathias Hänel, Christian Langer, Eleni Kapsali, Evangelos Briasoulis, Despoina Kyriakou, Izhar Hardan, Netanel A Horowitz, Cangialosi Clotilde, Francesco Fabbiano, Barbara Castagnari, Fabio Ciceri, Gerardo Musuraca, Andrzej Deptała, Janusz Kłoczko, Marius Balea, Ana-Maria Vladareanu, Victor Rossiev, Adrián Alegre, Cristina Encinas, Jorge Gayoso, Thomas Pabst, Neil Rabin, Sherri Arledge, Fernando Cabanillas, Joseph Catlett, Tarek Chidiac, David Clarkson, Madhav Dhodapkar, George Geils, Cyrus MA Khan, Entezam Sahovic, Mohamad Khasawneh, Rajesh Sehgal, Oscar Ballester, Moshe Levy, Joseph Fay, Kiem Liem, Matthew Lunning, Julie Vose, Edward Faber, Donald MacFarlane, Raymond Hohl, Tariq Mahmood, Birbal Bhaskar, Martha Mims, Ira Oliff, Agne Paner, John Maciejewski, Arvinda Padmanabhan, Robert Richard, Amit Sanyal, Gary Schiller, Harry Staszewski, Don Stevens, Christopher Vaughn, Kevin Windsor

Publikováno v: The Lancet Haematology. 9:e403-e414

BACKGROUND: Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::408fd2626647bda321f302f4c5f4b247
https://doi.org/10.1016/s2352-3026(22)00103-x